IDEAYA Biosciences, Inc.
IDYA
$28.32
$0.110.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.56M | 10.88M | 207.83M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.56M | 10.88M | 207.83M | -- | -- |
| Cost of Revenue | 95.73M | 86.60M | 82.99M | 74.23M | 70.89M |
| Gross Profit | -89.17M | -75.72M | 124.84M | -74.23M | -70.89M |
| SG&A Expenses | 19.38M | 18.85M | 16.39M | 14.58M | 13.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.10M | 105.45M | 99.38M | 88.81M | 84.39M |
| Operating Income | -108.54M | -94.57M | 108.45M | -88.81M | -84.39M |
| Income Before Tax | -98.54M | -83.27M | 119.24M | -77.49M | -72.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.54M | -83.27M | 119.24M | -77.49M | -72.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.54M | -83.27M | 119.24M | -77.49M | -72.18M |
| EBIT | -108.54M | -94.57M | 108.45M | -88.81M | -84.39M |
| EBITDA | -107.86M | -93.85M | 109.11M | -88.09M | -83.79M |
| EPS Basic | -1.11 | -0.94 | 1.35 | -0.88 | -0.82 |
| Normalized Basic EPS | -0.69 | -0.66 | 0.84 | -0.55 | -0.51 |
| EPS Diluted | -1.11 | -0.94 | 1.33 | -0.88 | -0.82 |
| Normalized Diluted EPS | -0.69 | -0.66 | 0.83 | -0.55 | -0.51 |
| Average Basic Shares Outstanding | 88.70M | 88.58M | 88.53M | 88.47M | 88.36M |
| Average Diluted Shares Outstanding | 88.70M | 88.58M | 89.69M | 88.47M | 88.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |